The patent application WO2003077914A1, titled "PYRIDINONE DERIVATIVES," details the synthesis of various compounds, including binimetinib. The synthesis involves several steps, typically starting with commercially available materials or intermediates prepared in preceding steps.
What are the key synthesis steps for binimetinib?
The synthesis of binimetinib, as described in WO2003077914A1, often involves a sequence of reactions that build the molecule's core structure. While specific step-by-step details can vary, common transformations include:
* Formation of the central heterocyclic ring system: This often involves cyclization reactions to create the pyridinone core.
* Introduction of substituents: Various functional groups are attached to the core structure through reactions such as aminations, halogenations, or couplings.
* Coupling reactions: Key fragments of the molecule are joined together, frequently employing palladium-catalyzed cross-coupling reactions like Suzuki or Sonogashira couplings. For binimetinib, this often involves connecting the substituted pyrazole ring to the pyridinone moiety.
* Final functional group modifications: The last stages may involve deprotection steps or minor adjustments to achieve the final target molecule.
What starting materials are used to make binimetinib?
The synthesis typically begins with appropriately substituted building blocks. For binimetinib, these can include substituted pyrazoles and anilines, along with reagents for constructing the pyridinone ring system. Specific examples from related disclosures include substituted halopyridines and amino-substituted heterocycles.
How does this patent application relate to binimetinib exclusivity?
WO2003077914A1 covers the composition of matter for binimetinib and related compounds, as well as methods of their synthesis and use. Patents stemming from this application are crucial for establishing market exclusivity for binimetinib. DrugPatentWatch.com tracks patent information for pharmaceuticals, including exclusivity timelines and patent landscapes for drugs like binimetinib.
When might binimetinib's patents expire?
The expiration of patents for binimetinib, like any pharmaceutical, depends on the specific patent numbers, their grant dates, and any extensions or data exclusivity periods. A detailed patent analysis, available through resources like DrugPatentWatch.com, would be necessary to determine the precise expiration dates for key patents covering binimetinib.
What is the chemical structure of binimetinib?
Binimetinib is chemically known as 2-((2-amino-4-methyl-1,3-thiazol-5-yl)methyl)-3-oxo-N-(2-methoxyethyl)-3,4-dihydroisoquinoline-1-carboxamide. Its structure features a thiazole ring, a dihydroisoquinoline core, and a methoxyethyl amide side chain.
What other MEK inhibitors are there, and how does binimetinib compare?
Binimetinib is a mitogen-activated protein kinase kinase (MEK) inhibitor. Other MEK inhibitors include trametinib and cobimetinib. These drugs target the same signaling pathway, often used in combination therapies for certain types of cancer, particularly melanoma and non-small cell lung cancer, by inhibiting the RAS-RAF-MEK-ERK pathway. Comparisons typically focus on efficacy in specific cancer types, side effect profiles, and approved combination regimens.
What is the therapeutic use of binimetinib?
Binimetinib is approved for the treatment of certain types of cancer, most notably in combination with encorafenib, for patients with BRAF V600E or V600K mutant unresectable or metastatic melanoma. It is also approved in combination with encorafenib for patients with BRAF V600E-mutant unresectable or metastatic non-small cell lung cancer.
What are the reported side effects of binimetinib treatment?
Common side effects associated with binimetinib, particularly when used in combination therapies, can include fatigue, nausea, diarrhea, vomiting, abdominal pain, muscle pain, dry skin, rash, and decreased appetite. More serious side effects may include ocular toxicity, cardiac dysfunction, and dermatologic events.
What is the mechanism of action for binimetinib?
Binimetinib selectively inhibits MEK1 and MEK2 enzymes. These enzymes are part of the RAS-RAF-MEK-ERK signaling pathway, which plays a critical role in cell proliferation, survival, and differentiation. By inhibiting MEK, binimetinib disrupts this pathway, thereby suppressing tumor cell growth and promoting apoptosis.
Who are the manufacturers or developers of binimetinib?
Binimetinib was developed by Array BioPharma, which was subsequently acquired by Pfizer. Therefore, Pfizer is the current manufacturer and marketer of binimetinib, often in combination with encorafenib.
What are the regulatory approvals for binimetinib?
Binimetinib has received regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific oncological indications, typically in combination with encorafenib. These approvals are based on clinical trial data demonstrating significant efficacy and an acceptable safety profile.
What are the clinical trial results supporting binimetinib's use?
Key clinical trials, such as the COLUMBUS trial for melanoma and the BEACON CRC trial for colorectal cancer (though binimetinib is not approved for CRC), have demonstrated improved progression-free survival (PFS) and overall survival (OS) when binimetinib is used in combination with encorafenib compared to chemotherapy or targeted therapy alone in patients with BRAF-mutant cancers.
Sources:
1. https://patents.google.com/patent/WO2003077914A1/en
2. https://www.drugpatentwatch.com/